HENGRUI PHARMA (600276.SS)

Compare

44.65

+0.01

+(0.02%)

At close: January 27 at 3:00:01 PM GMT+8

Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of 22.8%.

Clinical Trials Arena 14 days ago

600276.SS
+0.02%
GLDAF

LLY
Mainland-Traded Hengrui Pharma Files for Listing in Hong Kong

(Bloomberg) -- Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. filed to list its shares in Hong Kong, adding to the growing number of publicly traded mainland Chinese firms looking to have their stock trade in the financial hub.Most Read from BloombergNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeCan American Drivers Learn to Love Roundabouts?Don’t Shrink the BusIs This Weird Dome the Future of Watching Sports?Dutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Ch

Bloomberg 21 days ago

600276.SS
+0.02%
IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

IDEAYA Biosciences (IDYA) said Sunday it has entered into an exclusive licensing agreement with Jian

PREMIUM
MT Newswires 29 days ago

600276.SS
+0.02%
IDYA
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, SHA: 600276), an innovative global pharmaceutical company headquartered in China focused on unmet clinical needs. Under the terms of the agreement, IDEAYA wil

PR Newswire 30 days ago

IDYA

600276.SS
+0.02%
ESMO 2024: Can Jiangsu Hengrui Pharma disrupt the HER2-mGEJ treatment paradigm?

Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a challenge.

Clinical Trials Arena 4 months ago

600276.SS
+0.02%
Global Calcium hit with Form 483 after Indian factory inspection

The US Food and Drug Administration (FDA) cited concerns with the active pharmaceutical ingredient (API) manufacturing plant including falsifying production records and failing to follow proper document procedures.

Pharmaceutical Technology 4 months ago

600276.SS
+0.02%
Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data

The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.

BioPharma Dive 7 months ago

LLY

600276.SS
+0.02%
Western companies drive Chinese biotech licensing deal blitz

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers that have insufficient...

PREMIUM
Financial Times 7 months ago

600276.SS
+0.02%
Investors put $400M into biotech licensing obesity drugs from China

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

BioPharma Dive 8 months ago

600276.SS
+0.02%
30 Most Valuable Drug Companies in 2024

In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]

Insider Monkey 11 months ago

ABBV

NVO

LLY

Performance Overview

Return	600276.SS	SSE Composite Index
YTD	-3.23%	-4.60%
1-Year	+11.34%	+11.70%
3-Year	+7.40%	-5.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HENGRUI PHARMA (600276.SS)

Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial

Mainland-Traded Hengrui Pharma Files for Listing in Hong Kong

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

ESMO 2024: Can Jiangsu Hengrui Pharma disrupt the HER2-mGEJ treatment paradigm?

Global Calcium hit with Form 483 after Indian factory inspection

Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data

Western companies drive Chinese biotech licensing deal blitz

Investors put $400M into biotech licensing obesity drugs from China

30 Most Valuable Drug Companies in 2024

Performance Overview